Skip to main content
. Author manuscript; available in PMC: 2021 Jan 1.
Published in final edited form as: Methods Mol Biol. 2020;2055:23–60. doi: 10.1007/978-1-4939-9773-2_2

Table 4.

Development progress of LAG-3 inhibitors

Product Company and partner
(if applicable)		 Structure LAG-3 target and
ligand specificity		 Phase of development ORR
BMS-986016 (relatlimab) Bristol Myers Squibb Fully humanized, IgG4 Undisclosed Phase I dose-escalation (NCT01968109) 12.5%
MK-4280 Merck Fully humanized, IgG4 Undisclosed Phase I dose-escalation (NCT02720068) 6% (MK-4280); 20% (MK-4280/pembrolizumab)
LAG525 Novartis Fully humanized, IgG4 Undisclosed Phase I dose-escalation (NCT03365791) Unknown (LAG525); 10% (LAG525/spartalizumab)
OMP-313M32 (etigilimab) OncoMed Fully humanized, IgG4 Undisclosed Phase I dose-escalation (NCT03446040) No responses reported, 22% with prolonged stable disease
TSR-033 Tesaro and
GlaxoSmithKline		 Fully humanized, IgG4 Undisclosed Phase I dose-escalation (NCT03250832) Unreported
AB154 i-Mab Biopharma Undisclosed Undisclosed Phase I dose-escalation (NCT03628677) Unreported
IMP321 Prima BioMed/Immutep Undisclosed Undisclosed Phase I dose-escalation (NCT03252938) Unreported